Inhibrx Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Inhibrx kazanç ve gelirinin sırasıyla yıllık 9.1% ve 59.7% oranında artması tahmin edilirken, EPS'nin yıllık 13.1% oranında büyümesi bekleniyor.

Anahtar bilgiler

9.1%

Kazanç büyüme oranı

13.1%

EPS büyüme oranı

Biotechs kazanç büyümesi	28.3%
Gelir büyüme oranı	59.7%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	13 May 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique Platform

Nov 05

Inhibrx, Inc. (NASDAQ:INBX) Shares Could Be 38% Below Their Intrinsic Value Estimate

Mar 23

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGM:INBX - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	122	-296	N/A	N/A	1
12/31/2025	2	-361	N/A	N/A	1
12/31/2024	N/A	-316	N/A	N/A	2
3/31/2024	2	-271	-222	-216	N/A
12/31/2023	2	-241	-198	-193	N/A
9/30/2023	0	-189	-169	-167	N/A
6/30/2023	1	-172	-144	-144	N/A
3/31/2023	1	-163	-129	-128	N/A
12/31/2022	2	-145	-116	-115	N/A
9/30/2022	5	-125	-108	-107	N/A
6/30/2022	7	-111	-91	-90	N/A
3/31/2022	7	-94	-87	-86	N/A
12/31/2021	7	-82	-81	-80	N/A
9/30/2021	7	-78	-74	-73	N/A
6/30/2021	11	-78	-75	-73	N/A
3/31/2021	13	-75	-64	-62	N/A
12/31/2020	13	-76	-49	-48	N/A
9/30/2020	10	-75	-46	-45	N/A
6/30/2020	6	-74	-33	-31	N/A
3/31/2020	6	-68	-36	-34	N/A
12/31/2019	13	-51	-34	-32	N/A
9/30/2019	15	-40	-29	-27	N/A
6/30/2019	15	-30	-29	-27	N/A
3/31/2019	14	-26	-28	-27	N/A
12/31/2018	9	-31	-25	-23	N/A
9/30/2018	7	-35	-24	-23	N/A
12/31/2017	8	-19	N/A	-19	N/A
12/31/2016	7	-8	N/A	-18	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: INBX önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: INBX önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: INBX önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: INBX şirketinin gelirinin (yıllık 59.7% ) US pazarından (yıllık 8.9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: INBX şirketinin gelirinin (yıllık 59.7% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: INBX 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Inhibrx Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

No longer forecast to breakeven

Price target decreased by 20% to US$35.50

Consensus revenue estimates decrease by 22%, EPS upgraded

Consensus revenue estimates increase by 308%, EPS downgraded

Consensus revenue estimates increase by 26%

Consensus revenue estimates fall by 85%

Recent updates

Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique Platform

Inhibrx Files Form 15

Inhibrx: Continued Advancement Even After INBRX-101 Sale To Sanofi

Aventis Inc. completed the acquisition of Inhibrx, Inc. (NasdaqGM:INBX) from a group of shareholders.

Inhibrx, Inc.(NasdaqGM:INBX) dropped from NASDAQ Biotechnology Index

Two Separate Complaints with Nearly Identical Claims Filed in Supreme Court of State of New York, County of New York Against Inhibrx, Inc

Two Separate Complaints with Nearly Identical Claims Filed in Supreme Court of State of New York, County of New York Against Inhibrx, Inc

Is Inhibrx (NASDAQ:INBX) Using Debt Sensibly?

First quarter 2024 earnings released: US$1.44 loss per share (vs US$1.12 loss in 1Q 2023)

Executive VP & CFO notifies of intention to sell stock

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

Aventis Inc. entered into a definitive agreement to acquire Inhibrx, Inc. (NasdaqGM:INBX) for $1.4 billion.

Price target decreased by 20% to US$35.50

Aventis Inc. entered into a definitive agreement to acquire Inhibrx, Inc. (NasdaqGM:INBX) for $1.4 billion.

Aventis Inc. entered into a definitive agreement to acquire Inhibrx, Inc. (NasdaqGM:INBX) for $1.4 billion.

Consensus revenue estimates decrease by 22%, EPS upgraded

Consensus revenue estimates increase by 308%, EPS downgraded

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: US$1.10 loss per share (vs US$0.90 loss in 3Q 2022)

Inhibrx, Inc. Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma

Inhibrx, Inc. announced that it has received $200.000633 million in funding

Inhibrx, Inc. announced that it expects to receive $199.999961 million in funding

Consensus revenue estimates increase by 26%

New major risk - Negative shareholders equity

Second quarter 2023 earnings released: US$1.08 loss per share (vs US$0.97 loss in 2Q 2022)

Inhibrx, Inc. Grants Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 85%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Founder & Chief Scientific Officer notifies of intention to sell stock

Founder & Chief Scientific Officer notifies of intention to sell stock

Founder & Chief Scientific Officer notifies of intention to sell stock

Founder & Chief Scientific Officer notifies of intention to sell stock

Consensus forecasts updated

Inhibrx, Inc. Updates Efficacy and Safety Data from Ongoing Phase 1 INBRX-109 Expansion Cohorts for the Treatment of Chondrosarcoma

Consensus revenue estimates increase by 42%

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Founder & Chief Scientific Officer notifies of intention to sell stock

Founder & Chief Scientific Officer notifies of intention to sell stock

Inhibrx Announces Opportunity for Accelerated Approval Pathway on Functional AAT Serum Levels for INBRX-101 in AATD and Announces Bronchoalveolar Lavage Fluid Detection Results from the Phase 1 Study

Inhibrx down 8% after announcing webcast for pathway for rare disease candidate

Founder & Chief Scientific Officer notifies of intention to sell stock

Consensus revenue estimates fall by 22%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Founder & Chief Scientific Officer notifies of intention to sell stock

Inhibrx, Inc. Announces Completion of Phase 1 Combination Dose Escalation for INBRX-105

Inhibrx: Potential To Move To Registration Study With INBRX-101

High number of new and inexperienced directors

INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency and Demonstrates Potential to Achieve Normal Functional Alpha-1 Antitrypsin Levels with Monthly Dosing

Consensus revenue estimates fall by 17%

Inhibrx, Inc. to Host Webcast Presentation of Topline Results from the Phase 1 Trial of INBRX-101, its Optimized Recombinant Human AAT-Fc Protein for the Treatment of Alpha-1 Antitrypsin Deficiency

First quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

Price target decreased to US$49.67

Inhibrx, Inc. Announces Formation of A Scientific Advisory Board for Its INBRX-101 program

Inhibrx, Inc., Annual General Meeting, May 25, 2022

Inhibrx, Inc. (NASDAQ:INBX) Shares Could Be 38% Below Their Intrinsic Value Estimate

Price target decreased to US$49.67

Consensus forecasts updated

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Inhibrx, Inc. Announces Initial Phase 1 Dose Escalation Results for INBRX-106

Third quarter 2021 earnings released: US$0.54 loss per share (vs US$0.77 loss in 3Q 2020)

Price target increased to US$42.60

Second quarter 2021 earnings released: US$0.55 loss per share (vs US$0.98 loss in 2Q 2020)

Inhibrx, Inc.(NasdaqGM:INBX) dropped from Russell 3000E Value Index

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri